Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables

被引:2
|
作者
Wu, Beilei [1 ]
de Leon, Alexander R. [1 ]
机构
[1] Univ Calgary, Dept Math & Stat, Calgary, AB T2N 1N4, Canada
关键词
D O I
10.1002/bimj.201200254
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Regarding Paper Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables by T. Sozu, T. Sugimoto, and T. HamasakiBiometrical Journal (2012) 54(5): 716-729 Article: http://dx.doi.org/10.1002/bimj.201100221 Authors' Reply: http://dx.doi.org/10.1002/bimj.201300032 This paper recently introduced a methodology for calculating the sample size in clinical trials with multiple mixed binary and continuous co-primary endpoints modeled by the so-called conditional grouped continuous model (CGCM). The purpose of this note is to clarify certain aspects of the methodology and propose an alternative approach based on latent means tests for the binary endpoints. We demonstrate that our approach is more powerful, yielding smaller sample sizes at powers comparable to those used in the paper.
引用
收藏
页码:807 / 812
页数:6
相关论文
共 50 条
  • [1] Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. BIOMETRICAL JOURNAL, 2012, 54 (05) : 716 - 729
  • [2] "Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables" Reply
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. BIOMETRICAL JOURNAL, 2013, 55 (05) : 813 - 813
  • [3] Sample size determination in clinical trials with multiple co-primary binary endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. STATISTICS IN MEDICINE, 2010, 29 (21) : 2169 - 2179
  • [4] Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (04) : 650 - 668
  • [5] A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints
    Sugimoto, Tomoyuki
    Sozu, Takashi
    Hamasaki, Toshimitsu
    [J]. PHARMACEUTICAL STATISTICS, 2012, 11 (02) : 118 - 128
  • [6] Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints
    Huang, Wong-Shian
    Hung, Hui-Nien
    Hamasaki, Toshimitsu
    Hsiao, Chin-Fu
    [J]. PLOS ONE, 2017, 12 (06):
  • [7] Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes
    Homma, Gosuke
    Yoshida, Takuma
    [J]. PHARMACEUTICAL STATISTICS, 2024, 23 (01) : 46 - 59
  • [8] Sample size determination in group-sequential clinical trials with two co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Sugimoto, Tomoyuki
    Hayashi, Kenichi
    Evans, Scott R.
    Sozu, Takashi
    [J]. STATISTICS IN MEDICINE, 2014, 33 (17) : 2897 - 2913
  • [9] Power and Sample Size Determination in Clinical Trials with Multiple Primary Continuous Correlated Endpoints
    de Micheaux, Pierre Lafaye
    Liquet, Benoit
    Marque, Sebastien
    Riou, Jeremie
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (02) : 378 - 397
  • [10] Power analysis for cluster randomized trials with multiple binary co-primary endpoints
    Li, Dateng
    Cao, Jing
    Zhang, Song
    [J]. BIOMETRICS, 2020, 76 (04) : 1064 - 1074